Search Bar & Filters
Found 24 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are evaluating a new approach to selecting biologic treatments for adults with active Crohns Disease CD. This prospective, randomized study compares standard treatment selection to a method guided by epigenetic markers, aiming to assess which method better induces clinical remission and improves endoscopic response. The trial includes patients who are either new to biologic therapy or have used no more than one prior biologic treatment. The study is designed to measure efficacy, safety, and cost-effectiveness of this epigenome-guided approach. Participants are randomly assigned to one of two groups one receives biologic therapy based on epigenetic testing results using a specialized software called EpiPredict, which predicts response to two biologics, Vedolizumab VDZ or Ustekinumab UST. The other group receives biologic treatment chosen by their doctor following usual care guidelines without epigenetic information. Both groups receive their biologic treatments as labeled, with dosing adjustments allowed as needed by the treating physician. Throughout the 26-week treatment phase, participants undergo clinical assessments aligned with their biologic treatment schedules. Follow-up visits continue every six months up to two years, collecting data from medical records and online questionnaires. Researchers will measure clinical remission, endoscopic response, and cost-effectiveness among other outcomes to determine the value of using epigenetic markers in treatment selection for Crohns Disease.
Actively Recruiting
Researchers are evaluating the efficacy and safety of eloralintide compared with placebo in adults with persistent obesity or overweight. Participants may have type 2 diabetes or not, and all are on stable background therapy with a weekly incretin. This phase 3 randomized, double-blind study aims to understand the effects of eloralintide on body weight and related health outcomes. Participants will be randomly assigned to receive one of four doses of eloralintide or a placebo, all given by subcutaneous injection once weekly. The study treatment period lasts for 64 weeks, during which participants receive their assigned injections. This is a parallel group study, meaning each participant receives only one assigned treatment throughout the trial. Participant involvement spans about 80 weeks, including screening, treatment, and follow-up. Researchers will monitor changes in body weight, waist circumference, blood pressure, blood sugar, insulin, kidney function, inflammation markers, and quality of life using questionnaires. Safety and medication use will also be tracked. Visits and assessments will occur regularly to evaluate the treatment effects and participant well-being.
Actively Recruiting
Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.
Actively Recruiting
Researchers are evaluating a new treatment approach for colon cancer, focusing on a specific type called mismatch repair proficientmicrosatellite stable MMRpMSS colon cancer. This Phase 2 study compares a combination of dostarlimab with CAPEOX chemotherapy to CAPEOX chemotherapy alone. The study aims to find early signs of how well this combination works before surgery and to understand how blood and tumor markers might predict treatment response. Participants will be randomly assigned to receive either dostarlimab plus CAPEOX chemotherapy or CAPEOX chemotherapy alone. Both treatments are given before surgery, a process known as neoadjuvant therapy. The study includes two groups one receiving the combination treatment and the other receiving only chemotherapy. Treatment duration and follow-up are planned to assess response and safety. During the study, participants will undergo various assessments including tumor tissue collection via colonoscopy, evaluations of tumor response, and monitoring for adverse events. Researchers will measure major pathological response rates and track any side effects up to approximately 105 weeks. The study also looks at the percentage of participants who can undergo tumor removal surgery, and detailed pathological response rates. Safety and effectiveness are monitored throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Parkinsons disease PD is a neurological disorder that affects the brain and worsens over time, with symptoms such as tremors, stiffness, and slow movement. This research aims to assess how effective FoslevodopaFoscarbidopa is in treating adults with advanced Parkinsons Disease in Belgium under routine clinical practice. Approximately 120 adult participants prescribed this treatment will be studied across multiple sites. Participants will receive FoslevodopaFoscarbidopa through subcutaneous infusion as directed by their doctors according to local guidelines. This observational study does not involve additional interventions beyond routine care. Participants will continue their usual treatment while being followed for up to 18 months. During the study, participants will attend regular hospital or clinic visits as part of their standard care. Researchers will monitor changes in symptoms, focusing on OFF time periods when medication effects wear off measured by a specific Parkinsons rating scale over approximately six months. The study involves no extra procedures or burdens beyond routine practice and aims to collect data on the treatments impact over time.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of bowel cleansing using 100 g Mannitol compared to the standard Plenvu same-day dosing regimen for people undergoing elective colonoscopy. This Phase III international study aims to determine if Mannitol is not worse than Plenvu in preparing the bowel for colonoscopy. The study is randomized, parallel-group, and endoscopist-blinded to ensure unbiased results. Participants are randomly assigned to one of two groups. One group will self-administer a single dose of 100 g Mannitol dissolved in 1 liter of water within 45 minutes on the day of colonoscopy. The other group will follow a split-dose regimen of Plenvu the same day, involving dissolving doses in water and drinking specified amounts over a period with a waiting time between doses. Both groups consume a total of 2 liters of preparation liquid. During the study, participants will undergo colonoscopy within 28 days of signing consent, where bowel cleansing quality will be assessed using the Boston Bowel Preparation Scale. Researchers will also measure adenoma detection rate, cecal intubation rate, repeat colonoscopy rates, and presence of colonic bubbles. Participants must complete the entire study and follow instructions. Safety and patient acceptance will also be monitored throughout the trial period.
Actively Recruiting
Researchers are evaluating continuous glucose monitoring CGM compared to self-monitoring of blood glucose SMBG in women diagnosed with gestational diabetes GDM, including both early and late diagnoses. This randomized controlled trial RCT aims to study pregnancy outcomes and glucose control in women with GDM. The study is conducted across 16 centers in Belgium and Australia, focusing on how glucose monitoring methods affect health during pregnancy and postpartum. Participants will be randomly assigned to either the intervention group using the Freestyle Libre 3 real-time CGM device continuously until delivery or the control group using standard SMBG with a glucometer, following routine care. Both groups will wear a blinded CGM sensor Freestyle Libre Pro IQ during specific pregnancy periods to collect glucose data. Women diagnosed with early GDM will have additional blinded CGM monitoring. After delivery, all participants undergo a 75g oral glucose tolerance test OGTT between 6 and 24 weeks postpartum and wear a blinded CGM device during this follow-up. During the study, participants will receive education on managing GDM with lifestyle changes and glucose monitoring. Researchers will collect data on glucose levels, time spent in target glucose ranges, hypoglycemia episodes, insulin use, pregnancy outcomes, and quality of life at various pregnancy stages and postpartum. The main outcome is a composite measure of pregnancy results at delivery. The trial includes monitoring physical activity, diet, symptoms of anxiety and depression, treatment satisfaction, and breastfeeding duration. Participation ends after the postpartum OGTT and follow-up assessments.
1-10 of 24
1